Next-generation sequencing (NGS) panels are increasingly used to identify genomic alterations that extend therapeutic opportunities for patients who progress beyond therapies approved by the US Food and Drug Administration yet remain candidates for treatment.1,2 Metastatic basal cell carcinoma (mBCC) is a deadly manifestation of the most commonly diagnosed skin cancer, with a mutational landscape primarily focused on the sonic hedgehog pathway (SHH), including patched homologue 1 (PTCH1) and smoothened homologue (SMO).3 Unfortunately once progression or therapy intolerance occurs, therapeutic options are limited. Thus genomic profiling of mBCC has emerged as a critical component of disease management. We report a case of a patient with mBCC who experienced a 9-month complete metabolic response (CR) after treatment with pazopanib, an agent targeting a kinase insert domain receptor (KDR) mutation.
Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS. Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. JAMA Dermatol. 2017;153(6):607–609. doi:10.1001/jamadermatol.2017.0187
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: